Catalyst Pharmaceuticals (CPRX) Reports Record Q4 and Full Year 2025 Results [Yahoo! Finance]
Catalyst Pharmaceuticals, Inc. (CPRX)
Last catalyst pharmaceuticals, inc. earnings: 3/16 05:26 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.catalystpharma.com
Company Research
Source: Yahoo! Finance
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX ) is one of the best cheap biotech stocks to buy now . Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) reported record fiscal Q4 and record full year 2025 financial results on February 25. Total revenues for the full year 2025 came up to $589.0 million, reflecting a 19.8% year-over-year growth and marking another year of record total revenues for the company. Total revenues for fiscal Q4 2025 were $152.6 million, supported by an 18.3% FIRDAPSE® growth and 67.5% growth of AGAMREE®, which shows continued adoption. Catalyst Pharmaceuticals, Inc. (CPRX): Among Stocks with Consistent Growth to Buy Now Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) expects total revenues for the full year 2026 to be in the $615 million and $645 million range, which, according to management, shows confidence in the strength and durability of the FIRDAPSE and AGAMREE franchises. The company attributed strong fiscal Q4 2025 performance to the ongoing organic product
Show less
Read more
Impact Snapshot
Event Time:
CPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CPRX alerts
High impacting Catalyst Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CPRX
News
- Catalyst Pharmaceuticals (CPRX) was upgraded by Zacks Research from "hold" to "strong-buy".MarketBeat
- Catalyst Pharmaceuticals (CPRX) had its price target raised by Citigroup Inc. from $33.00 to $35.00. They now have a "buy" rating on the stock.MarketBeat
- Is Catalyst Pharmaceuticals (CPRX) Pricing Reflect Its Strong DCF Upside After Recent Flat Returns [Yahoo! Finance]Yahoo! Finance
- Catalyst Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]Yahoo! Finance
- Catalyst Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
CPRX
Earnings
- 2/25/26 - Beat
CPRX
Sec Filings
- 2/25/26 - Form 8-K
- 2/25/26 - Form 10-K
- 2/19/26 - Form 4
- CPRX's page on the SEC website